Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EX Other protein kinase inhibitors
L01EX03 Pazopanib
D05380 Pazopanib hydrochloride (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Multitargeted Kinase Inhibitors
Pazopanib
D05380 Pazopanib hydrochloride (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D05380 Pazopanib hydrochloride (JAN/USAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
D05380 Pazopanib hydrochloride
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
PDGFR
D05380 Pazopanib hydrochloride (JAN/USAN) <JP/US>
KIT (CD117)
D05380 Pazopanib hydrochloride (JAN/USAN) <JP/US>
VEGFR family
VEGFR1 (FLT1)
D05380 Pazopanib hydrochloride (JAN/USAN) <JP/US>
VEGFR2 (KDR)
D05380 Pazopanib hydrochloride (JAN/USAN) <JP/US>
VEGFR3 (FLT4)
D05380 Pazopanib hydrochloride (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D05380
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D05380
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D05380
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D05380
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D05380